Sensitivity, specificity, positive predictive value, negative predictive value and accuracy of neuropathy diabetes score (NDS) compared with the Michigan neuropathy screening instrument (MNSI)

MNSI is widely used for evaluation of distal symmetric peripheral polyneuropathy (PPN) in individuals with diabetes. In the DCCT/EDIC study, the MNSI was validated for screening of signs and symptoms of PPN, presenting, for a cutoff of ≥2.5, sensitivity of 61%, specificity of 79%, positive predictive value (PPV) of 55% and negative (NPV) of 83%, when compared to neurological examination in combination with nerve conduction studies as gold standard. To evaluate the sensitivity, specificity, PPV, NPV and accuracy of Neuropathy Diabetes Score (NDS) (≥3.0) compared to MNSI score, used as the gold standard.